

# Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/R486E7AF28EFEN.html>

Date: August 2019

Pages: 100

Price: US\$ 3,500.00 (Single User License)

ID: R486E7AF28EFEN

## Abstracts

Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019

### SUMMARY

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosine-protein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin-1 (NRG1) and is activated by it. It also activated by CSPG5.

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 3, 1, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Gastric Cancer, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Lung Cancer, Solid Tumor, Esophageal Squamous Cell Carcinoma (ESCC), Gallbladder Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Colorectal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary), Esophageal Cancer, Gastroesophageal (GE) Junction

Carcinomas, Hypopharyngeal Cancer, Laryngeal Cancer, Lung Adenocarcinoma, Metastatic Biliary Tract Cancer, Metastatic Hepatocellular Carcinoma (HCC), Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Paranasal Sinus And Nasal Cavity Cancer, Sarcomas, Thyroid Cancer and Triple-Negative Breast Cancer (TNBC).

The latest report Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019, outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development

ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)  
- Overview

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)  
- Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)  
- Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)  
- Companies Involved in Therapeutics Development

Aslan Pharmaceuticals Ltd

AstraZeneca Plc

AVEO Oncology Inc

Celldex Therapeutics Inc

Etubics Corp

Hanmi Pharmaceuticals Co Ltd

Hummingbird Bioscience Pte Ltd

Imugene Ltd

MediaPharma SRL

Merus NV

Novartis AG

Takis Srl

XuanZhu Pharma Co Ltd

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

- Drug Profiles

AV-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Inhibit EGFR and ERBB3 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-3379 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elgemtumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FCN-411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMBD-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-5209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCLA-125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPEV-201959 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit EGFR, ERBB2 and ERBB3 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poziotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TK-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HER1, HER2, HER3 and IGF1R for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HER3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HER3 for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varlitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-5491 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

- Dormant Products

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

- Discontinued Products

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

- Product Development Milestones

Featured News & Press Releases

Appendix



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indications, H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Products under Development by Companies, H2 2019 (Contd..2), H2 2019  
Products under Development by Companies, H2 2019 (Contd..3), H2 2019  
Products under Development by Companies, H2 2019 (Contd..4), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by Aslan Pharmaceuticals Ltd, H2 2019  
Pipeline by AstraZeneca Plc, H2 2019  
Pipeline by AVEO Oncology Inc, H2 2019  
Pipeline by Celldex Therapeutics Inc, H2 2019  
Pipeline by Etubics Corp, H2 2019  
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019  
Pipeline by Hummingbird Bioscience Pte Ltd, H2 2019  
Pipeline by Imugene Ltd, H2 2019  
Pipeline by MediaPharma SRL, H2 2019  
Pipeline by Merus NV, H2 2019  
Pipeline by Novartis AG, H2 2019  
Pipeline by Takis Srl, H2 2019  
Pipeline by XuanZhu Pharma Co Ltd, H2 2019  
Dormant Products, H2 2019  
Dormant Products, H2 2019 (Contd..1), H2 2019  
Dormant Products, H2 2019 (Contd..2), H2 2019  
Dormant Products, H2 2019 (Contd..3), H2 2019  
Dormant Products, H2 2019 (Contd..4), H2 2019  
Discontinued Products, H2 2019  
Discontinued Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019 (Contd..2), H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Aslan Pharmaceuticals Ltd

AstraZeneca Plc

AVEO Oncology Inc

Celldex Therapeutics Inc

Etubics Corp

Hanmi Pharmaceuticals Co Ltd

Hummingbird Bioscience Pte Ltd

Imugene Ltd

MediaPharma SRL

Merus NV

Novartis AG

Takis Srl

XuanZhu Pharma Co Ltd

## I would like to order

Product name: Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/R486E7AF28EFEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R486E7AF28EFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970